French pharmaceutical company Sanofi and US-based bio-technology company Enteris BioPharma have reached an agreement to perform a feasibility study to develop an oral formulation of one of the former’s pre-clinical stage peptides with the help of Peptelligence, a patented oral peptide and small molecule delivery platform owned by the latter.

The investigational oral therapeutic is meant to treat type 2 diabetes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Ukraine-based chemical company Enamine and Swiss-based pharmaceutical company Actelion Pharmaceuticals have expanded their early drug discovery agreement that is focused on cardiovascular and central nervous system disorders, immunology, infectious diseases and oncology.

Expansion of the agreement was originally signed in 2005 and enables Enamine to produce exclusive screening compounds by decorating scaffold compounds supplied by Actelion with Enamine’s building blocks.

"US-based Ritter Pharmaceuticals will study the role of the microbiome and RP-G28 in metabolic syndrome with the help of University of Nebraska, under an agreement signed between the two."

US-based Ritter Pharmaceuticals will study the role of the microbiome and RP-G28 in metabolic syndrome with the help of University of Nebraska, under an agreement signed between the two.

See Also:

The agreement is aimed at the development of microbiome therapeutics in metabolic syndrome.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tetra Bio-Pharma subsidiary PhytoPain Pharma has signed a clinical research agreement with Sante Cannabis.

The partnership is aimed at the development of late-phase clinical trial protocols needed to evaluate the safety and efficacy of PPP001 so that prescription drug approval could be obtained from regulatory authorities in Canada and the US.